Vertex Pharmaceuticals (VRTX) Saham Harga
Vertex Pharmaceuticals Harga
Selama 19 tahun terakhir pendapatan Vertex Pharmaceuticals tumbuh 23,6% per tahun, mencapai 12,07 miliar USD. Laba per saham tumbuh 40,3% per tahun selama 14 tahun terakhir. Bagi Vertex Pharmaceuticals, margin bersih sebesar 32,7% naik dibanding 30,9% beberapa tahun lalu. Target harga konsensus 12 bulan untuk Vertex Pharmaceuticals adalah 580,00 USD, sekitar di atas harga saat ini 12,8%. Dari 39 analis, 32 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Vertex Pharmaceuticals
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Vertex Pharmaceuticals
Pertanyaan yang sering diajukan tentang saham Vertex Pharmaceuticals
The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.
Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.
Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.
Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.
Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.
Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.
Analis saat ini menetapkan target harga rata-rata 553,08 USD untuk saham Vertex Pharmaceuticals (median: 580,00 USD), yaitu +7,5 % terhadap harga terbaru. Konsensus didasarkan pada 39 peringkat analis.
39 analis saat ini menilai saham Vertex Pharmaceuticals: 32 merekomendasikan beli, 6 tahan, dan 1 jual. Untuk 2026, analis memperkirakan Vertex Pharmaceuticals menghasilkan pendapatan 13,25 miliar USD dan laba per saham 18,51 USD.
Dengan kurs saat ini, saham Vertex Pharmaceuticals diperdagangkan pada 459,71 EUR (514,26 USD).
Saham Vertex Pharmaceuticals (VRTX) tercatat di 11 bursa, termasuk: NASDAQ (VRTX), London (0QZU.L), SIX (Zürich) (VRTX.SW), XETRA (VX1.DE), Frankfurt (VX1.F), München (VX1.MU), Düsseldorf (VX1.DU), Hamburg (VX1.HM).
Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.
Pendapatan diperkirakan dari Vertex Pharmaceuticals adalah 13,25 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Vertex Pharmaceuticals adalah 4,74 miliar USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Vertex Pharmaceuticals saat ini adalah 27,78. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Vertex Pharmaceuticals.
Rasio harga-terhadap-penjualan (PSR) Vertex Pharmaceuticals saat ini adalah 9,94. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Vertex Pharmaceuticals.
Skor Kualitas AlleAktien untuk Vertex Pharmaceuticals adalah 5/10.
ISIN dari Vertex Pharmaceuticals adalah US92532F1003. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Vertex Pharmaceuticals adalah 882807. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Vertex Pharmaceuticals adalah VRTX. Simbol ticker digunakan untuk memperdagangkan saham Vertex Pharmaceuticals di bursa saham.
Saham Vertex Pharmaceuticals
Kelompok Peer Vertex Pharmaceuticals
Vertex Pharmaceuticals Ticker
Vertex Pharmaceuticals FIGI
Semua metrik fundamental dan analisis mendalam Vertex Pharmaceuticals
Analisis saham kami untuk saham Vertex Pharmaceuticals mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Vertex Pharmaceuticals. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.